Atlas Trials

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Clinical trial NCT05396573 · UNKNOWN

Trial details

NCT number
NCT05396573
Sponsor
Walvax Biotechnology Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
COVID-19
Start date
2022-07-01
Primary completion
2022-08-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.